Aktieanalys

Cantargia: New Strategy in Pancreatic Cancer - Redeye

{newsItem.title}

Redeye Publicerad: 16 May 2023 07:22

Redeye comments on Cantargia's new strategy to study nadunolimab in a controlled phase IIb study in pancreatic cancer, which we believe is more shareholder-friendly.

Länk till analysen i sin helhet: https://www.redeye.se/research/908059/cantargia-new-strategy-in-pancreatic-cancer?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt